RFA-CA-13-001
Early-Stage Innovative Molecular Analysis Technology Development for Cancer Research (R21)
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-13-001.html
Companion FOAs:
RFA-CA-13-002, R33 Validation and Advanced Development of Emerging Molecular Analysis
Technologies for Cancer Research
RFA-CA-13-003, R21 Early-Stage Development of Innovative Technologies for Biospecimen Science
RFA-CA-13-004, R33 Validation and Advanced Development of Emerging Technologies for
Biospecimen Science
Due date: 9/20/2013
Project duration: 3 years
Direct budget: $500,000/year
Earliest anticipated start date: 7/1/2014
This FOA solicits grant applications proposing exploratory research projects focused on the inception and
development of early stage, highly innovative, technologies or emerging technol ogies with significant
transformative potential that has not yet been explored in a cancer-relevant use. An emerging technology is
defined (for the purpose of this FOA) as one that has passed the initial developmental stage, but has not
yet been evaluated within the context of a cancer-relevant intended use and requires significant
modification for the proposed application.
RFA-OD-13-011
Tobacco Control Regulatory Research (R01)
http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-13-011.html
also as R21: http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-13-010.html
and as R03: http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-13-012.html
Due date: 1/15/2014
Project duration: 5 years
Direct budget: $500,000/year
Earliest anticipated start date: 10/1/2014
Purpose: to encourage biomedical, behavioral, and social science research that will inform the development
and evaluation of regulations on tobacco product manufacturing, distribution, and ma rketing. Research
projects must address the research priorities related to the regulatory authority of the Food and Drug
Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention
and Tobacco Control Act (FSPTCA), Public Law 111-31. The awards under this FOA will be administered by
NIH using designated funds from the FDA CTP for tobacco regulatory science. Research results from this
FOA are expected to generate findings and data that are directly relevant to inform t he FDA's regulation of
the manufacture, distribution, and marketing of tobacco products to protect public health.
PAR-13-190
Detection of Pathogen-Induced Cancer (DPIC) (R01)
http://grants.nih.gov/grants/guide/pa-files/PAR-13-190.html
Due date: 12/11/2013 (next, 7/10/2014)
Project duration: 5 years
Direct budget: $250,000/year (or more)
Earliest anticipated start date: 7/1/2014
Purpose: to encourage research projects which focus on the interactions of carcinogenic pathogens with the
human microbiome and the host for the detection of pathogen-induced cancer (DPIC). This FOA
encourages research to assess molecular signatures associated with risk and early detection of pathogeninduced cancer and chronic inflammation associated with progression to invasive cancer.
PAR-13-189
Imaging and Biomarkers for Early Cancer Detection (R01)
http://grants.nih.gov/grants/guide/pa-files/PAR-13-189.html
Due date: 12/11/2013 (next, 7/10/2014)
Project duration: 5 years
Direct budget: $250,000/year (or more)
Earliest anticipated start date: 7/1/2014
Purpose: to facilitate collaborative imaging and biomarker research to improve cancer screening, early
cancer detection and diagnosis by integrating multi modality imaging strategies and multiplexed biomarker
methodologies.
PAR-13-185
Image-guided Drug Delivery in Cancer (R01)
http://grants.nih.gov/grants/guide/pa-files/PAR-13-185.html
Due date: 11/19/2013 (next, 6/19/2014)
Project duration: 5 years
Direct budget: $250,000/year
Earliest anticipated start date: 7/1/2014
Purpose: to support innovative research projects that are focused on image-guided drug delivery (IGDD),
including real-time image guidance, monitoring, quantitative in vivo characterizations and validation of
delivery and response. It will support research in development of integrated imaging -based platforms for
multifunctional and multiplexed drug delivery systems in cancer and other diseases, quantitative imaging
assays of drug delivery, and early intervention.
PAR-13-159
The Role of Microbial Metabolites in Cancer Prevention and Etiology (U01)
Due date: 11/14/2013 (next, 11/14/2014)
Project duration: 5 years
Direct budget: $250,000/year
Earliest anticipated start date: 7/1/2014
Purpose: preclinical and clinical research that will describe the effect of microbially generated metabolites in
cancer prevention/ progression and the molecular mechanisms underlying these effects:
proliferative/apoptotic responses, cytokine production, inflammatory and immunomodulatory effects locally
and/or distant. This FOA encourages pre-clinical and clinical studies that will describe the variability in the
bacterial metabolites production and their contribution to cancer prevention/promotion among va rious
racial and ethnic groups. Due to inconsistent responses to dietary interventions, this research is necessary
to identify who might benefit from specific dietary recommend ations and who might be placed at risk. It is
important to identify the factors that contribute to differences in response to foods and food components
and to identify early markers that will identify those who will receive maximum benefits from dietary
change.
PAR-12-095
Basic Cancer Research in Cancer Health Disparities (U01)
http://grants.nih.gov/grants/guide/pa-files/PAR-12-095.html
Companion FOAs: PAR-12-094, R21 Exploratory/Developmental Grant
Due date: 6/20/2013 (next, 11/20/2013)
Project duration: 5 years
Direct budget: $250,000/year
Earliest anticipated start date: 4/1/2014
Purpose: Through this Funding Opportunity Announcement, the Center to Reduce Cancer Health Disparities
(CRCHD), the Division of Cancer Biology (DCB) and Division of Cancer Prevention (DCP), at the Nat ional
Cancer Institute (NCI), encourage grant applications from investigators interested in conducting basic,
mechanistic research into the biologic/genetic causes of cancer health disparities. These cooperative
agreement research awards (U01) will support innovative studies designed to investigate biological/genetic
bases of cancer disparities, and may include the development and testing of new methodologies and
models, secondary data analyses, and mechanistic studies of identified biological factors assoc iated with
cancer disparities, including those related to basic research in prevention strategies.
PAR-12-049
Cancer Education Grants Program (R25)
http://grants.nih.gov/grants/guide/pa-files/PAR-12-049.html
Due date: 5/25/2013 (next, 9/25/2013)
Project duration: 5 years
Direct budget: $300,000/year
Earliest anticipated start date: 4/1/2014
Purpose: The NIH Research Education (R25) grant mechanism supports creative and innovative research
education programs for the development of biomedical, behavioral, and clinical researchers, or for
education and outreach on health-related research to a variety of audiences. Research education grants are
not typical research instruments. The awards are intended to support institutional educational programs but
not research projects. Applications must include a plan to evaluate the educational activities proposed (see
Section IV, Evaluation Plan) and a plan for disseminating results (see Section IV, Dissemination Plan).
PAR-12-039
Small Grants Program for Cancer Epidemiology (R03)
http://grants.nih.gov/grants/guide/pa-files/PAR-12-039.html
Due date: 7/23/2013 (next, 11/19/2013)
Project duration: 2 years
Total direct budget: $100,000
Earliest anticipated start date: 4/1/2014
Purpose: This funding opportunity announcement encourages the submission of Small Research Grant (R03)
applications for research on cancer etiology and epidemiology. The overarching goal of this FOA is to
provide support for pilot projects, testing of new techniques, secondary analyses of existing data,
development and validation of measurement methods, linkage of genetic polymorphisms with other
variables related to cancer risk, and development of innovative projects for more comprehensive research in
cancer etiology and epidemiology.
PAR-12-140
Role of the Microflora in the Etiology of Gastro-Intestinal Cancer (R01)
http://grants.nih.gov/grants/guide/pa-files/PAR-12-140.html
Due date: 7/2/2013 (next, 11/1/2013)
Project duration: 5 years
Direct budget: $250,000/year
Earliest anticipated start date: 4/1/2014
Purpose: This Funding Opportunity Announcement, issued by the National Cancer Institute and the
National Institute on Alcohol Abuse and Alcoholism, encourages innovative multidisciplin ary research
projects that will advance our mechanistic understanding of microflora influences on Gastro -Intestinal (GI)
carcinogenesis. This FOA seeks applications that leverage and integrate information from large, meta -omic
data sets to guide studies that identify critical microbial activities that can be mechanistically linked to GI
carcinogenesis. Applicants may draw from existing large data sets, and may also propose to generate
appropriate new data, including but not limited to data from both gene an d protein analysis, such as DNA
sequence and copy number, post-translational modifications, secreted signals, and protein-protein
interaction data between host factors and individual microbial species, or communities of microbes.
........................................................................................
KUCC Grants Development Office
........................................................................................
Anca Geana, MBA, CRA
Grants Coordinator
Univ. of Kansas Cancer Center
Phone: 913-945-6323
e-mail: ageana@kumc.edu